BART owns the patent on breast cancer genes . Myriad offers four test that catches most abnormalities , then charges $ nearly everyone $ 700 for third . Now , Klein and others offer BART to all their patients , but many ca n't do it because of the cost . Company defends Myriad Genetics test , based on separate technology .
BART owns the patent on breast cancer genes . Myriad offers four test that catches most abnormalities , then charges $ nearly everyone $ 700 for third . Company defends Myriad Genetics test , based on separate technology .